Merck expects no writedowns for Zetia, Vytorin cholesterol drugs

November 10, 2014 8:34 PM

13 0

(Reuters) - Merck & Co on Monday said long-awaited data from an 18,000-patient trial suggest the company will not have to write down the value of its blockbuster Zetia and Vytorin cholesterol drugs.

"The company has determined that the Zetia and Vytorin intangible assets are not impaired," the No. 2 U.S. drugmaker said on Monday in a regulatory filing, noting its assessment was based on having seen "unblinded" data from the huge study.

Read more

To category page